SIGHT SCIENCES INC (SGHT)
Health Care · Ophthalmology medical devices · NASDAQ
Sight Sciences develops minimally invasive interventional devices for glaucoma and dry eye, targeting ophthalmology markets through reimbursement-focused commercialization.
What SIGHT SCIENCES INC does
Sight Sciences is an ophthalmology medical device company that develops and commercializes minimally invasive interventional solutions for eye diseases. The company focuses on two primary product areas: Interventional Glaucoma treatments and Interventional Dry Eye solutions. Sight Sciences designs devices aimed at treating these conditions through novel procedural approaches, with a business model centered on obtaining and maintaining reimbursement while scaling sales to existing and new customers.
Themes: ["ophthalmology / eye care","glaucoma treatment","dry eye treatment","minimally invasive medical devices","interventional procedures"]
Fundamentals
- Price$5.26 as of 2026-07-09 close
- Market cap$286M as of 2026-07-10
- 1-year return+50.9% as of 2026-07-09 close
- Net margin-46.8% as of 2026-07-10
- Gross margin+86.9% as of 2026-07-10
- ROE-59.1% as of 2026-07-10
- Debt / equity0.75 as of 2026-07-10
- Revenue growth (YoY)+1.9% as of 2026-07-10
- Revenue CAGR (3y)+2.7% SEC XBRL
- Beta2.46 as of 2026-07-10
Key risks (from latest filing)
["Reimbursement risk: ability to obtain and maintain sufficient reimbursement for Interventional Glaucoma products and establish broad reimbursement for Interventional Dry Eye products","Regulatory and competitive risk: need to compete effectively with existing competitors and new market entrants in a highly competitive and rapidly changing environment","Capital and financing risk: need for additional financing and ability to maintain compliance with secured credit facility terms"]
Competitors & peers
- Alcon
- Bausch + Lomb
- Johnson & Johnson Vision
- Glaukos
- Ivantis
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.